Drug profile · INN
bictegravir
BIKTARVY
bictegravir (BIKTARVY) is a human immunodeficiency virus type 1 integrase inhibitor.
Drug details — bictegravir
- Class
- Antiinfectives for systemic use (J05)
- Route
- —
- Patents
- 0
- Programs
- 14
- Data quality
- 0.83
Quick answer
bictegravir (BIKTARVY) is a human immunodeficiency virus type 1 integrase inhibitor.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 integrase inhibitor
Primary target: Human immunodeficiency virus type 1 integrase
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
This page should frame the KRX English IR reference as a company disclosure/investor-relations document and give readers a concise way to navigate its purpose and likely themes. Keep the summary factual and avoid adding performance or product claims not present in the source.
FDA Grants Priority Review for Gilead's Bictegravir Plus Lenacapavir HIV Treatment Combination
Gilead Sciences receives FDA priority review for novel once-daily HIV treatment combining bictegravir and lenacapavir, potentially the smallest single-tablet regimen.
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
FDA approves Merck's IDVYNSO (doravirine/islatravir), the first non-INSTI, tenofovir-free two-drug HIV regimen showing non-inferior efficacy to BIKTARVY.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bictegravir?
bictegravir (BIKTARVY) is a human immunodeficiency virus type 1 integrase inhibitor.
What is the brand name for bictegravir?
BIKTARVY is a marketed brand name for bictegravir. Check FDA Drugs@FDA for the current US label holder and prescribing information.